Five proposals submitted this spring to Johns Hopkins’ Idea Lab crowdsourcing website will receive funding by virtue of garnering the most support in online voting.
Funding will be awarded to a health care innovation conference that expands upon the popular MedHacks event, a science-themed summer camp for Baltimore fifth-graders, and a place for students to get free food left over from events, among other creative concepts.
The Big Idea CONNECTpreneur Summer Forum Tysons Corner – June 13, 2017
“The Best Networking Event in the MidAtlantic.”
This will be our 24th consecutive SOLD OUT event over the last 6 years!
Over 70% of previous attendees surveyed say that CONNECTpreneur is the “Number One” tech and investor event in the Mid-Atlantic region!
DCInno calls CONNECTpreneur “The Best Networking Event in DC” and a “NETWORKING JACKPOT” of the Region’s TOP Entrepreneurs, Business Leaders, CXOs, Angels, and VCs.
This UNIQUE EVENT is like NONE OTHER in our region, because of the high quality of our attendees, speakers and presenters.
And YES, the networking is unprecedented!
Altimmune, Inc. (Nasdaq:ALT), a clinical stage immunotherapeutic biotechnology company, will visit the Nasdaq MarketSite in Times Square.
In honor of the occasion, Bill Enright, Chief Executive Officer, will ring the Opening Bell.
Altimmune, Inc. (Nasdaq:ALT) announced today the completion of its merger with PharmAthene, Inc., effective May 4, 2017. Upon the completion of the merger, the combined company was renamed Altimmune, Inc., and will commence trading on The NASDAQ Capital Market under the ticker symbol “ALT” on May 5, 2017. The combined company is a fully integrated and diversified immunotherapeutics company with one preclinical-stage and four clinical-stage drug-development programs.
What’s the definition of “doing the same thing repeatedly and expecting a different result?” If you said “a good idea,” you might want to consider a career in politics.
Many in Congress want to impose price controls on medicines that result from federally funded research. We’ve tried this before, and it nearly brought medical research and development to a halt.
The Greater Washington Partnership (Partnership), a group of leading CEOs and entrepreneurs aimed at addressing the critical economic issues facing the Greater Washington region, announced today the addition of four board members to its 17-person founding Board of Directors, bringing the total to 21. Joining the Partnership board will be:
Emergent BioSolutions Inc. (NYSE:EBS) today held a ribbon-cutting ceremony led by Dr. Rick Bright, director of the Biomedical Advanced Research and Development Authority (BARDA), and Daniel J. Abdun-Nabi, Emergent’s president and chief executive officer, to mark the formal opening of the company’s newly expanded Center for Innovation in Advanced Development and Manufacturing (CIADM) at its Bayview Campus in Baltimore. The facility is one of three centers designated by the U.S. Department of Health and Human Services to provide advanced development and manufacturing of medical countermeasures to support the U.S. government’s national security and public health emergency needs.
During the 2017 FLC national meeting in San Antonio, Texas, the FLC held its annual elections for open positions to serve on the Executive Board and as regional officers. While absentee ballots were available from March 24 – April 18, onsite voting took place April 25 – 26 and was open to Consortium Representatives whose memberships are registered with the Consortium Recording Secretary.
Business leaders hope to elevate Greater Washington to top three biotech clusters in U.S. Yeah, good luck.
GAITHERSBURG, Md., May 04, 2017 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq:ALT) announced today the completion of its merger with PharmAthene, Inc., effective May 4, 2017. Upon the completion of the merger, the combined company was renamed Altimmune, Inc., and will commence trading on The NASDAQ Capital Market under the ticker symbol “ALT” on May 5, 2017. The combined company is a fully integrated and diversified immunotherapeutics company with one preclinical-stage and four clinical-stage drug-development programs.
